



September 29, 2026

Company Name: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Security Code: 7575; TSE Prime Market)
Inquiries: Takeyoshi Egawa, Director and CFO
(TEL. +81-3-6711-5200)

Japan Lifeline Announces Acquisition of U.S.-Based Cross Vascular and Change in Specified Subsidiary Following Capital Increase

TOKYO, JAPAN - September 29, 2026 - Japan Lifeline Co., Ltd. ("the Company") announced that its Board of Directors, at a meeting held today, resolved to acquire all shares of Cross Vascular, Inc. (Headquarters: Solana Beach, CA, U.S.A.; President and CEO: Brad Klos; hereinafter "Cross Vascular"), a U.S. company that develops products related to transseptal puncture, an essential procedure for arrhythmia ablation treatment. The shares will be acquired through JLL Med USA Inc. (hereinafter "JLL Med USA"), a wholly owned subsidiary of the Company, making Cross Vascular an indirect wholly owned subsidiary (hereinafter the "Acquisition").

In conjunction with the Acquisition, JLL Med USA has also resolved to implement a capital increase for Cross Vascular (hereinafter the "Capital Increase"). As a result, the capital of Cross Vascular will equal or exceed 10% of the Company's capital, thereby falling under the category of a specified subsidiary (indirect wholly owned subsidiary) of the Company. Details are announced below.

1. Reason for the Acquisition

As part of its long-term growth strategy, the Company has decided to acquire U.S.-based Cross Vascular to accelerate the global expansion of its in-house products and establish a business foundation in the United States, the world's largest market. While the Company has established a leading position in Japan in EP/Ablation, its core business in the arrhythmia area, it intends to expand into the global market, which is expected to experience continued high growth.

Cross Vascular develops innovative products for transseptal puncture, including RF needles and RF generators and has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). Cross Vascular has also established a U.S. intellectual property portfolio that includes four patents issued by the United States Patent and Trademark Office (USPTO).

Regarding the strategic significance of the Acquisition, Keisuke Suzuki, President and CEO of the Company, stated the following: "The aim of this acquisition is to significantly accelerate our U.S. business by incorporating Cross Vascular's FDA-cleared RF transseptal products into our global portfolio. We established JLL Med USA as a local subsidiary in August 2026. JLL Med USA will serve as the foundation for our commercial operations in the U.S. market. By leveraging Cross Vascular's technology and accelerating our global expansion, we intend to drive sustainable growth across the Group and enhance long-term shareholder value."

2. Overview of Cross Vascular, Inc.

(1)	Name	Cross Vascular, Inc.		
(2)	Location	535 Stevens Ave. W., Solana Beach, CA, U.S.A.		
(3)	Representative	Brad Klos, President and Chief Executive Officer		
(4)	Description of Business	Development of radiofrequency systems for transseptal puncture		
(5)	Share Capital	USD 8,900		
(6)	Date of Establishment	April 14, 2020		
(7)	Major Shareholders and Ownership Ratios	Not disclosed based on the intentions of the relevant shareholders		
(8)	Relationship Between the Company and the Target Company	Capital relationship	Not applicable	
		Personnel relationship	Not applicable	
		Business relationship	Not applicable	
(9)	Results of Operations and Financial Condition for the Last Three Years			
	Fiscal Year (thousands of USD)	FYE Dec 2023	FYE Dec 2024	FYE Dec 2025
	Net assets	(3,011)	(3,088)	(3,091)
	Total assets	174	114	113
	Net assets per share (USD)	(0.33)	(0.34)	(0.34)
	Net sales	-	-	-
	Operating profit	(585)	(77)	(2)
	Profit (Net loss)	(585)	(77)	(2)
	Earnings per share (USD)	(0.06)	(0.00)	(0.00)
	Dividend per share	-	-	-

(Note: Negative figures are indicated in parentheses.)

3. Overview of the counterparty to the share acquisition

The overviews of the counterparties are not disclosed based on the intentions of the counterparties. There are no capital, personnel, or business relationships required to be stated between the Company and the counterparties.

4. Overview of JLL Med USA

(1)	Name	JLL Med USA Inc.
(2)	Location	16802 Aston Street, Irvine, CA. 92606 USA.
(3)	Representative	Nobuo Takahashi, President and Chief Executive Officer
(4)	Business Description	Development and sales of medical devices

(5) Share Capital	USD 10,400,000	
(6) Date of Establishment	August 25, 2026	
(7) Major Shareholder and Ownership Ratio	Japan Lifeline Co., Ltd. / 100%	
(8) Relationship Between the Company and the Target Company	Capital relationship	The Company holds 100% of its shares.
	Personnel relationship	Directors of the Company concurrently serve as directors of the subsidiary.
	Business relationship	There is no business relationship to be disclosed at this time.

Note: As JLL Med USA was established on August 25, 2026, there are no financial figures available.

5. Number of shares to be acquired, acquisition price, and shareholding before and after acquisition

(1) Number of Shares Held Before Transfer	0 shares (Number of voting rights: 0, Percentage of voting rights held: 0%)
(2) Number of Shares to Be Acquired	8,900,000 shares (Number of voting rights: 8,900,000)
(3) Acquisition Price	Common shares for Cross Vascular: USD 4,734 thousand (Approx. JPY 743 million calculated at USD 1 = JPY 157) <i>(This includes USD 734 thousand to be paid upon completion of the Acquisition, and a maximum of USD 4,000 thousand as earn-out consideration)</i> Advisory fees and other related expenses: Approx. JPY 234 million Total (estimated amount): Approx. JPY 977 million
(4) Number of Shares Held After Transfer	8,900,000 shares (Number of voting rights: 8,900,000; Percentage of voting rights held: 100%)

6. Schedule

(1) Date of Board of Directors Resolution	September 29, 2026
(2) Date of Contract Execution	September 30, 2026 (Scheduled)
(3) Date of Share Transfer Execution	September 30, 2026 (Scheduled)

7. Overview of the Capital Increase (Capital Increase from JLL Med USA to Cross Vascular)

(1) Date of Decision	September 29, 2026
(2) Amount of Capital Increase	USD 7,265 thousand
(3) Capital After Increase	USD 7,274 thousand
(4) Ownership Ratio After Increase	100%
(5) Reason for Capital Increase	Debt payments, working capital, and other corporate purposes

8. Future Outlook

The impact of the Acquisition and the Capital Increase on the Company's business results will be immaterial. The Company will promptly announce any matters that require disclosure should they arise in the future.